VisionGate Adds Three Prominent Board Directors

more No Comments June 5 2014

Lung cancer test shows high senstitivity, specificity, and early stage detection

more No Comments May 23 2014

New Study Shows High Sensitivity and Specificity for VisionGate’s LuCED® Test to Help Detect Lung Cancer Earlier

more No Comments May 15 2014

VisionGate to Present Early Lung Cancer Detection Data at ASCO

more No Comments May 7 2014

VisionGate featured in Oct 2013 Nature Article

VisionGate, Inc. was just featured in a Nature article in Oct. 2013. You can also read the article on the Nature website.

more No Comments November 14 2013

IASLC 2013 Poster: Non-invasive Detection of Lung Cancer from Cells in Sputum Using Cell-CT™

more No Comments October 28 2013

VisionGate Presents Clinical Data at IASLC Meeting Showing its Cell-CT 3D Imaging Platorm detects Lung Cancer with High Sensitivity and Specificity

more No Comments October 28 2013

IASLC 2011: VisionGate To Present At IASLC Meeting showing how adjunctive use of its 3D cell imaging platform can increase utility of CT screening for Lung Cancer

more No Comments October 15 2013

VisionGate Updates

As VisionGate was preparing for a busy Fall season with the generation of clinical data for lung cancer screening using its LuCED test, the U.S. Preventive Services Task Force electrified the lung cancer community with its draft recommendation that older Americans at high risk of lung cancer get screened every year with a low-dose x-ray CT scan (for more on the recommendations, click here.)  This recommendation is based on a landmark NCI study showing that CT screening reduces lung cancer deaths by 20%. The report then went on to highlight the major disadvantage of CT screening, which is a high false positive rate.  High false positive results would generate a great deal of follow-up testing that is costly, burdensome and ultimately unnecessary, and they could result in fewer at-risk people receiving lung cancer screening.


One key message is that reimbursement for lung cancer screening is now emerging. The other is that the high rate of false positive results in CT screening is good news for VisionGate. This is because VisionGate’s LuCED test can be launched initially as a non-invasive, cost-effective adjunct to CT screening to pinpoint the true positives while minimizing the false positives – using CT scanning in conjunction with LuCED means that those patients receiving a positive result would actually have lung cancer. With this important development as context, VisionGate scientists will present the initial results of a pilot clinical study using LuCED and the Cell-CTTM 3D cell analysis system at the prestigious IASLC World Conference on Lung Cancer in late October.


In addition, VisionGate CEO Alan Nelson will discuss the Cell-CT technology as a keynote speaker at the Single Cell Analysis Summit in mid-September.  We also anticipate that VisionGate’s technology may again be featured in an upcoming Nature publication, one of the most respected science journals. We are looking forward to these opportunities to raise the profile of VisionGate’s breakthrough Cell-CT technology among key scientific and industry audiences, as the company advances its LuCED clinical program.

more No Comments August 19 2013

Dr. Alan Nelson named Research Fellow at International Prevention Research Institute

Dr. Alan Nelson, CEO of VisionGate, has been recently named a Research Fellow at International Prevention Research Institute.

The International Prevention Research Institute (iPRI) is an independent research institute with a staff of demonstrated world-class excellence and leadership. iPRI has unparalleled experience in epidemiological research and macro health planning with a record of delivering real health and economic value to a range of public and private sources including governments, universities, research institutes, non-governmental organisations and large multi-national concerns. More information can be found at the link above.


more No Comments August 7 2013

Copyright 2019 - VisionGate, Inc.